- CagriSema, a combination of cagrilintide and semaglutide, was tested in a 68-week trial.
- The trial involved 2,728 type 2 diabetes patients inadequately controlled with metformin.
- CagriSema 2.4 mg/2.4 mg achieved a 1.91% HbA1c reduction and 14.2% weight loss.
- 43% of participants achieved ≥15% weight loss with CagriSema 2.4 mg/2.4 mg.
Trial Overview
REIMAGINE 2, part of the global REIMAGINE clinical trial program, was a 68-week efficacy and safety trial. It investigated the effects of once-weekly subcutaneous CagriSema, a fixed-dose combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide, in two different doses (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) compared to semaglutide and cagrilintide alone, as well as a placebo.
Participant Details
The trial included 2,728 participants with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor. Approximately 40% of participants were using an SGLT2 inhibitor before starting the trial.
Key Findings
From a mean HbA1c baseline of 8.2%, participants treated with CagriSema 2.4 mg/2.4 mg achieved a superior HbA1c reduction of 1.91%-points after 68 weeks, compared to 1.76%-points with semaglutide 2.4 mg. From a mean baseline body weight of 101 kg, CagriSema 2.4 mg/2.4 mg resulted in a superior weight loss of 14.2% after 68 weeks, compared to 10.2% with semaglutide 2.4 mg. No weight loss plateau was observed at week 68 for CagriSema.
Weight Loss Achievements
With CagriSema 2.4 mg/2.4 mg, 43% of participants achieved a weight loss of ≥15%, and 24% achieved a weight loss of ≥20%.
